Teva Pharms Company Profile

✉ Email this page to a colleague

What is the competitive landscape for TEVA PHARMS, and when can generic versions of TEVA PHARMS drugs launch?

TEVA PHARMS has three hundred and eighteen approved drugs.

There are two US patents protecting TEVA PHARMS drugs. There are forty-four tentative approvals on TEVA PHARMS drugs.

There are seventeen patent family members on TEVA PHARMS drugs in twelve countries and nine hundred and fifteen supplementary protection certificates in eighteen countries.

Summary for Teva Pharms

International Patents:	17
US Patents:	2
Tradenames:	264
Ingredients:	259
NDAs:	318

Drugs and US Patents for Teva Pharms

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	CAPSULE;ORAL	213256-001	Jan 6, 2021		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Teva Pharms	DICLOFENAC SODIUM	diclofenac sodium	TABLET, DELAYED RELEASE;ORAL	074459-001	Jun 25, 1997		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Teva Pharms	LEVETIRACETAM	levetiracetam	TABLET;ORAL	078101-001	Jan 15, 2009		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Teva Pharms	METHYLPHENIDATE HYDROCHLORIDE	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	078873-003	Jul 19, 2012	AB2	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Teva Pharms	ATENOLOL	atenolol	TABLET;ORAL	074120-001	Feb 24, 1995		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Teva Pharms Usa	OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE	amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	202491-001	Nov 3, 2016	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Teva Pharms Usa	ABIRATERONE ACETATE	abiraterone acetate	TABLET;ORAL	208432-001	Oct 31, 2018	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Teva Pharms

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-001	Feb 1, 2007	7,820,203	⤷ Try a Trial
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-001	Feb 1, 2007	7,829,121	⤷ Try a Trial
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	6,054,430	⤷ Try a Trial
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-001	Feb 1, 2007	8,877,245	⤷ Try a Trial
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	6,342,476	⤷ Try a Trial
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	7,199,098	⤷ Try a Trial
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-001	Feb 1, 2007	7,544,372	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for TEVA PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	for Injection	3.5 mg/vial	➤ Subscribe	2016-10-26
➤ Subscribe	Injection	40 mg/mL, 1 mL pre-filled syringe	➤ Subscribe	2014-01-29
➤ Subscribe	for Injection	100 mcg/vial and 500 mcg/vial	➤ Subscribe	2015-04-14
➤ Subscribe	Extended-release Capsule	15 mg and 30 mg	➤ Subscribe	2008-08-11
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03
➤ Subscribe	Injection	40 mg/mL, 1 mL pre-filled syringe	➤ Subscribe	2014-02-26
➤ Subscribe	for Injection	200 mcg/vial	➤ Subscribe	2015-05-01

Premature patent expirations for TEVA PHARMS

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date
⤷ Try a Trial	⤷ Try a Trial

International Patents for Teva Pharms Drugs

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
European Patent Office	1443933	⤷ Try a Trial
Japan	4794816	⤷ Try a Trial
Japan	2009102408	⤷ Try a Trial
Portugal	1443933	⤷ Try a Trial
World Intellectual Property Organization (WIPO)	03020252	⤷ Try a Trial
Austria	451106	⤷ Try a Trial
Spain	2334774	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Teva Pharms Drugs

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2269603	122015000094	Germany	⤷ Try a Trial	PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/09/538/001 20120723
0503785	91330	Luxembourg	⤷ Try a Trial	CERTIFICATE TITLE: UNE COMBINAISON D'OLMESARTAN MEDOXOMIL, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET D'HYDROCHLOROTHIAZIDE (OLMETEC PLUS)
1532149	C300569	Netherlands	⤷ Try a Trial	PRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN COMBINATIE MET METFORMINEHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/12/780/001-028 20120720
1343782	CA 2010 00024	Denmark	⤷ Try a Trial	PRODUCT NAME: PAZOPANIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER HYDROCLORID
0914118	PA2007001,C0914118	Lithuania	⤷ Try a Trial	PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006-08-28, EU/1/06/356/002 2006-08-28, EU/1/06/356/003 2006-08-28, EU/1/06/356/004 2006-08-28, EU/1/06/356/005 2006-08-28, EU/1/06/356/00 20060828
1663240	122016000109	Germany	⤷ Try a Trial	PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINER THERAPEUTISCH AEQUIVALENTEN, DURCH DAS GRUNDPATENT GESCHUETZTEN FORM DAVON, Z.B. EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN. EMTRICITABIN UND TENOFOVIRALAFENAMID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/16/1112 20160621
1343782	28/2010	Austria	⤷ Try a Trial	PRODUCT NAME: PAZOPANIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/10/628/001 - EU/1/10/628/004 20100614
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Summary for Teva Pharms

Paragraph IV (Patent) Challenges for TEVA PHARMS drugs

Premature patent expirations for TEVA PHARMS

Expiration due to failure to pay maintenance fee

Similar Applicant Names

Make Better Decisions: Try a trial or see plans & pricing